ArticleHaematologica2011
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.
Article in Haematologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 60 citations in OpenAlex.
- Advances in Designer Materials for Chronic Wound Healing.Advances in wound care · 2025Review
- Risk of drug-induced pericardial effusion: a disproportionality analysis of the FAERS database.BMC pharmacology & toxicology · 2025Article
- Review
- Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment.Cancers · 2024Review
- Dasatinib-Induced Bilateral Pleural Effusions.Cureus · 2022Article
- Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls.Vascular health and risk management · 2022Article
- Variables associated with pulmonary hypertension screened by echocardiography in chronic myeloid leukemia patients on dasatinib therapy.Frontiers in cardiovascular medicine · 2022Article
- Dasatinib-Induced Pleural and Pericardial Effusions.Cureus · 2021Article
- Pleural Effusion Secondary to Dasatinib Following Allogenic Hematopoietic Stem Cell Transplantation.The American journal of case reports · 2021Article
- Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study.Targeted oncology · 2021Article
- Cardiotoxicity of Novel Targeted Hematological Therapies.Life (Basel, Switzerland) · 2020Review
- Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase.British journal of clinical pharmacology · 2018Article
- Comprehensive review of cardiovascular toxicity of drugs and related agents.Medicinal research reviews · 2018Review
- Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.Leukemia research · 2017Review
- The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.Blood advances · 2017Article
- Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA-ROCK pathway.Cancer medicine · 2017Article
- Dasatinib Induced Cardiac Tamponade-A Rare Association.Journal of clinical and diagnostic research : JCDR · 2017Article
- A Case of Dasatinib-Induced Hemorrhagic Colitis Diagnosed by the Lymphocyte Transformation Test in a Chronic Myeloid Leukemia Patient.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016Article
- The role of dasatinib in the management of chronic myeloid leukemia.Drug design, development and therapy · 2015Review
- Bosutinib for the Treatment of Philadelphia Chromosome-Positive Leukemias.Expert opinion on orphan drugs · 2015Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dasatinib is considered an effective drug in imatinib-resistant chronic myeloid leukemia. Although reported to be well-tolerated, severe events such as pleural or pericardial effusion have been reported at 140 mg daily. We examined our chronic myeloid leukemia patients treated with dasatinib at 100 mg or 50 mg daily and identified 4 of 13 patients who developed marked effusion formation. In 2 patients, grade III/IV pleural and/or pericardial effusions were recorded. All 4 patients had received previous anti-leukemia therapy but none had pre-existing cardiac or pulmonary diseases. In 3 patients, dasatinib had to be discontinued despite treatment with diuretics and glucocorticosteroids. In conclusion, dasatinib-treated chronic myeloid leukemia patients are at risk for the development of pleural and pericardial effusions even when the drug is administered at 100 mg or 50 mg daily. Therefore, all patients should be examined for pre-existing comorbidity and risk factors before starting dasatinib and all should have repeated chest X-rays during long-term dasatinib therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.